Roche (RO.SW) announced that the European Commission has granted conditional marketing authorisation of Lunsumio, or mosunetuzumab, subcutaneous for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Approval is based on results from the phase I/II GO29781 study. Phase III studies involving Lunsumio SC are ongoing.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said: "Developing new formulations of our medicines is part of our commitment to offering greater flexibility and a better treatment experience for patients."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.